Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2016 Jun 1.
Published in final edited form as: Crit Care Med. 2015 Jun;43(6):1165–1169. doi: 10.1097/CCM.0000000000000940

The Presence of Hypothermia within 24 Hours of Sepsis Diagnosis Predicts Persistent Lymphopenia

Anne M Drewry a, Brian M Fuller a,b, Lee P Skrupky c, Richard S Hotchkiss a,d
PMCID: PMC4700928  NIHMSID: NIHMS744870  PMID: 25793436

Abstract

Objective

To determine whether hypothermia within 24 hours of sepsis diagnosis is associated with development of persistent lymphopenia, a feature of sepsis-induced immunosuppression

Design

Retrospective cohort study

Setting

1200-bed university-affiliated tertiary care hospital

Patients

Adult patients diagnosed with bacteremia and sepsis within 5 days of hospital admission between January 1, 2010 and July 31, 2012

Interventions

None

Measurements and main results

Leukocyte counts were recorded during the first four days following sepsis diagnosis. Persistent lymphopenia was defined as an absolute lymphocyte count less than 1.2 cells/μl x 103 present on the fourth day after diagnosis. Of the 445 septic patients included, 64 (14.4%) developed hypothermia (defined as a body temperature less than 36.0°C) within 24 hours of sepsis diagnosis. Hypothermia was a significant independent predictor of persistent lymphopenia (adjusted OR 2.70 [95% CI 1.10, 6.60], p =.03) after accounting for age, disease severity, comorbidities, source of bacteremia, and type of organism. Compared to the non-hypothermic patients, hypothermic patients had higher 28-day (50.0% vs. 24.9%, p < .001) and 1-year mortality (60.9% vs. 47.0%, p = .001).

Conclusions

Hypothermia is associated with higher mortality and an increased risk of persistent lymphopenia in septic patients, and it may be an early clinical predictor of sepsis-induced immunosuppression.

Keywords: sepsis, hypothermia, fever, body temperature, lymphopenia, immunosuppression

Introduction

Fever is considered to be an adaptive response to infection, and in vitro and animal studies have shown that elevated temperatures augment several aspects of humoral and cellular immunity (1). Yet, 20% of septic patients present to the hospital with hypothermia rather than fever. These patients have twice the mortality of febrile patients even after accounting for factors such as age, disease severity, and comorbidities (2). Although there is limited data to explain why these patients have worse outcomes, clear evidence links body temperature to infection risk. Clinical studies have demonstrated increased rates of surgical wound infections in hypothermic perioperative patients, and a recent meta-analysis showed an association between therapeutic hypothermia and sepsis in post-cardiac arrest patients (3,4). Additionally, a trial of systemic hypothermia in neonates with hypoxic ischemic encephalopathy found persistently depressed levels of total leukocytes and lymphocytes in patients who were cooled (5).

To date, most clinical investigations of the effect of hypothermia on immune function have been limited to patients undergoing induced therapeutic hypothermia rather than in septic patients presenting with spontaneous hypothermia. Only two previous studies have attempted to assess the immune status of hypothermic septic patients. Marik et al found no differences in circulating levels of IL-6, TNFα, or soluble TNFα receptors between hypothermic and febrile septic patients, while Arons et al observed increased plasma levels of IL-6 and TNFα as well as increased urinary excretion of cyclooxygenase-derived lipid mediators in hypothermic patients, suggesting a dysregulated inflammatory response (6,7). It is unknown whether hypothermic patients exhibit immune dysfunction that is not apparent with quantitative cytokine measurements.

Sepsis activates both pro- and anti-inflammatory mechanisms and can lead to extended periods of immunosuppression (8). One feature of sepsis-induced immunosuppression is apoptotic loss of immune cells, including T and B cells. Persistent lymphopenia has been associated with increased risks of mortality and nosocomial infection (9,10). Although patients treated with induced therapeutic hypothermia have been shown to develop lymphopenia (5), investigation of lymphopenia as a potential link between spontaneous hypothermia and increased mortality in septic patients has not been performed. Thus, the objective of this study was to examine the relationship between hypothermia and persistent lymphopenia in septic patients. We hypothesized that patients who presented with hypothermia within 24 hours of sepsis diagnosis would be more likely to develop persistent lymphopenia than non-hypothermic patients.

Materials and methods

Study design, setting, and population

This was a post-hoc analysis of a retrospective cohort study conducted at a 1,200-bed university-affiliated hospital between January 1, 2010 and July 31, 2012. It was approved by the Human Research Protection Office at our institution with waiver of informed consent. All patients with positive blood cultures drawn within five days of admission to the hospital and a diagnosis of sepsis were eligible for inclusion. Sepsis was diagnosed by the presence of at least two systemic inflammatory response syndrome (SIRS) criteria within 24 hours of the time the positive culture was collected (11). Exclusion criteria included: diagnosis of immunological disease or treatment with immunosuppressant medication within 6 months prior to or during the hospitalization (see Supplemental Table 1, Supplemental Digital Content 1, which lists of the specific immunosuppressive medications and immunological diseases that led to exclusion).

Patients were divided into two cohorts, hypothermic or non-hypothermic, based on their lowest body temperature within 24 hours of sepsis diagnosis (identified by the time of their first positive blood culture). Hypothermia was defined as a temperature less than 36.0°C, consistent with the definition of hypothermia in the SIRS criteria (11).

Data collection

Baseline demographics, daily leukocyte counts, and clinical outcomes were collected by a research assistant blinded to the patients’ temperatures. The first 24-hour period following the culture collection time was considered to be day 1; the next 24-hour period, day 2; etc. If multiple leukocyte counts were collected in a 24-hour period, the mean value was reported. Lymphopenia was defined as an absolute lymphocyte count less than 1.2 cells/μL x 103, which is the lower limit of normal at our institution.

The primary outcome was development of persistent lymphopenia, defined as lymphopenia present on day 4 following sepsis diagnosis. Day 4 was chosen based on previous work from our group demonstrating that septic patients with lymphopenia persisting to day 4 after sepsis diagnosis had increased mortality compared to those whose absolute lymphocyte counts recovered to normal (9). Secondary outcomes included 28-day mortality, 1-year mortality, intensive care unit (ICU) length of stay (LOS), and hospital LOS.

Statistical analysis

Descriptive statistics, including mean (standard deviation) and median (interquartile range), were used to describe the patient cohorts. Normality was assessed using histograms and the Kolmogorov-Smirnov Test. Baseline characteristics were compared using independent-samples t-tests (for normally distributed data), Mann-Whitney U tests (for non-normally distributed data), or chi square tests (for categorical data).

Kaplan-Meier survival curves were compared with log-rank tests to assess the relationship between hypothermia and 28-day and 1-year mortality. To determine the independent effect of hypothermia on the development of persistent lymphopenia after accounting for multiple confounders, multivariable logistic regression was used to model the odds of lymphopenia on day 4. Hypothermia, age, Acute Physiology and Chronic Health Evaluation (APACHE) II score, and the presence of at least one comorbidity were chosen a priori to be included in the model to control for underlying characteristics which might predispose patients to persistent lymphopenia. Other independent variables were included in the multivariable model if significant at a p value of .05 during univariable comparisons of baseline characteristics in patients with and without persistent lymphopenia. Collinearity diagnostics, including variance inflation factors, tolerance statistics, and variance proportions, were evaluated to ensure variable independence.

All statistical tests were carried out using SPSS 21.0 (SPSS Inc., Chicago, IL, USA). All tests were two-tailed and p values less than .05 were considered statistically significant.

Results

A total of 445 patients met the inclusion and exclusion criteria during the study period. Sixty-four patients were included in the hypothermic group and 381 patients in the non-hypothermic group. In the hypothermic and non-hypothermic groups respectively, 23 (35.9%) and 87 (22.8%) patients died or were discharged prior to day 4 or did not have complete blood counts sampled on day 4 (detailed in Supplemental Figure 1, Supplemental Digital Content 2). This resulted in 41 patients in the hypothermic group and 294 patients in the non-hypothermic group who were available for analysis of persistent lymphopenia.

Table 1 reports baseline characteristics and outcomes of the two groups. Hypothermic patients had higher APACHE II scores (median 20.5 [IQR 15.0, 27.8] vs. 16.0 [13.0, 20.0], p < .001) and a higher incidence of a pulmonary source of bacteremia (29.7% vs. 14.7%, p = .03). Gram-negative infections occurred in 51.6% of hypothermic patients versus 34.6% of non-hypothermic patients (p = .053).

Table 1.

Comparison of baseline characteristics and outcomes of hypothermic and non-hypothermic patients

Hypothermic
n = 64
Non-hypothermic
n = 381
p
Baseline characteristics
Age (years), mean (SD) 64.6 (16.9) 61.5 (15.2) .20a
Sex (male), n (%) 36 (56.3) 219 (57.5) .85b
APACHE II, median (IQR) 20.5 (15.0, 27.8) 16.0 (13.0, 20.0) <.001c
Source of bacteremia, n (%) .03b
 Lung 19 (29.7) 56 (14.7)
 Abdomen 14 (21.9) 74 (19.4)
 Urinary tract 8 (12.5) 53 (13.9)
 Central line 3 (4.7) 52 (13.6)
 Bone or soft tissue 10 (15.6) 65 (17.1)
 Other/unknown 10 (15.6) 81 (21.3)
Organism, n (%) .053b
 Gram-positive 23 (35.9) 178 (46.7)
 Gram-negative 33 (51.6) 132 (34.6)
 Fungal 1 (1.6) 22 (5.8)
 Polymicrobial 7 (10.9) 49 (12.9)
Hospital-acquired bacteremia, n (%) 9 (14.1) 53 (13.9) .97b
Time to appropriate antibiotic coverage (hours), median (IQR) 4.0 (1.4, 17.5) 4.3 (0.9, 16.6) .92c
Comorbidities, n (%)
 Coronary artery disease 23 (35.9) 115 (30.2) .36b
 Cerebrovascular disease 15 (23.4) 61 (16.0) .14b
 Congestive heart failure 15 (23.4) 110 (28.9) .37b
 Diabetes 22 (34.4) 149 (39.1) .24b
 Chronic renal insufficiency 20 (31.3) 93 (24.4) .47b
 Liver disease 13 (20.3) 64 (16.8) .49b
 COPD 21 (32.8) 122 (32.0) .90b
Temperature data
Lowest body temperature within 24 hours of sepsis diagnosis (°C), median (IQR) 35.5 (34.4, 35.8) 36.5 (36.2, 36.7) <.001c
Highest body temperature within 24 hours of sepsis diagnosis (°C), median (IQR) 37.1 (36.6, 38.2) 38.3 (37.5, 39.2) <.001c
Outcomes
Persistent lymphopeniad,e, n (%) 34 (82.9) 176 (59.9) .004b
28-day mortality, n (%) 32 (50.0) 95 (24.9) <.001f
1-year mortality, n (%) 39 (60.9) 179 (47.0) .001f
ICU length of stayg (days), median (IQR) 3.7 (1.9, 6.4) 3.1 (1.8, 6.9) .84c
Hospital length of stayg (days), median (IQR) 14.1 (8.2, 21.0) 11.0 (6.7, 20.7) .44c
a

Independent-samples t test.

b

Chi square test.

c

Mann-Whitney U test.

d

Absolute lymphocyte count less than 1.2 cells/μL x 103 on the fourth day after sepsis diagnosis.

e

Percentage based on total number of patients available for evaluation on day 4 (hypothermic, n = 41; non-hypothermic, n = 294).

f

Log-rank test.

g

Includes only patients who survived to ICU or hospital discharge.

SD, standard deviation; APACHE, Acute Physiology and Chronic Health Evaluation; IQR, 25%, 75% interquartile range; COPD, chronic obstructive pulmonary disease; ICU, intensive care unit.

The median absolute lymphocyte count on day 1 was similar between the hypothermic and non-hypothermic groups (0.71 [IQR 0.48, 1.14] vs. 0.66 [0.42, 1.09], p = .52). By day 4, the median absolute lymphocyte count was significantly lower in the hypothermic group (0.82 [IQR 0.64, 0.97] vs. 1.02 [0.68, 1.45], p = .02), and a greater percentage of the hypothermic patients had developed persistent lymphopenia (82.9% vs. 59.9%, p = .004) (Table 1). Hypothermic patients were also more likely to die by day 28 (50.0% vs. 24.9%, p < .001) and 1 year (60.9% vs. 47.0%, p = .001) (Kaplan-Meier curves shown in Supplemental Figure 2, Supplemental Digital Content 3). No differences in ICU and hospital LOS were observed between the two groups (Table 1).

Comparisons of baseline characteristics in patients who did and did not develop persistent lymphopenia are shown in Supplemental Table 2 (Supplemental Digital Content 4). Incidence of hypothermia, APACHE II score, source of bacteremia, and type of organism were significantly different between these two groups. The multivariable analysis to model the odds of developing persistent lymphopenia is shown in Table 2. Significant predictors of persistent lymphopenia included hypothermia (adjusted OR 2.70 [95% CI 1.10, 6.60], p =.03) and APACHE II score (adjusted OR 1.07 [95% CI 1.02, 1.13], p = .006). A catheter-related source of bacteremia was protective (adjusted OR 0.33 [95% CI 0.13, 0.83], reference pulmonary source, p = .02).

Table 2.

Multivariable logistic regression analysis for persistent lymphopeniaa (n = 335)

Adjusted ORb (95% CI) p
Hypothermiac 2.70 (1.10, 6.60) .03
Age 1.01 (0.99, 1.02) .49
APACHE IId 1.07 (1.02, 1.13) .006
Comorbiditye 1.05 (0.56, 1.99) .87
Organism
 Gram-positive Reference --
 Gram-negative 1.25 (0.67, 2.33) .48
 Fungal 2.96 (0.85, 10.23) .09
 Polymicrobial 0.46 (0.23, 1.06) .07
Source of bacteremia
 Pulmonary Reference --
 Intra-abdominal 0.95 (0.39, 2.28) .90
 Urinary tract 0.49 (0.19, 1.28) .15
 Catheter-related 0.33 (0.13, 0.83) .02
 Bone or soft tissue 0.43 (0.18, 1.02) .06
 Other/unknown 0.77 (0.33, 1.82) .55
a

Absolute lymphocyte count less than 1.2 cells/μL x 103 on the fourth day after sepsis diagnosis.

b

For continuous variables, odds ratios reflect the increased odds of developing persistent lymphopenia for a one unit increase in the variable. For categorical variables, the reference category is absence of the condition, except where otherwise specified.

c

Body temperature less than 36.0°C within 24 hours of sepsis diagnosis.

d

Temperature and age components removed.

e

At least one comorbidity present.

OR, odds ratio; CI, confidence interval; APACHE, Acute Physiology and Chronic Health Evaluation

Discussion

Persistent lymphopenia is a feature of sepsis-induced immunosuppression and a predictor of mortality in septic patients (9). This study demonstrates that hypothermic septic patients are more likely to develop persistent lymphopenia. It also confirms the results of previous studies associating hypothermia with short-term mortality (2,12) and extends the data further by showing an increased risk of death at one year. These findings have prognostic and therapeutic implications and suggest areas for further study.

Sepsis-induced immunosuppression contributes to mortality in septic patients by inhibiting pathogen clearance and increasing susceptibility to nosocomial infections (3). Recent developments in immunostimulatory therapy suggest that these treatments have potential to improve clinical outcomes in septic patients when specifically targeted to patients with quantitative evidence of immune dysfunction (13,14). However, determining which patients are most likely to be immunosuppressed and optimizing timing of these treatments remains a challenge. Identifying early clinical predictors of sepsis-induced immunosuppression, such as hypothermia, could assist physicians in selecting the most appropriate candidates for additional immunological testing in future trials or clinical applications of immunostimulatory therapy.

This study has several limitations. First, a persistently low absolute lymphocyte count is just one feature of sepsis-induced immunosuppression. Sepsis-induced immunosuppression is characterized by numerous alterations in both the adaptive and innate immune systems including increased immune cell apoptosis, CD4 and CD8 T cell exhaustion, shift from a T helper 1 (TH1) to TH2 phenotype, expansion of the regulatory T cell population, decreased HLA-DR expression on antigen presenting cells, impaired phagocytosis, and altered cytokine secretion (3). As a retrospective analysis, our evaluation of the association between hypothermia and sepsis-induced immunosuppression was restricted to variables acquired during routine clinical care. We could not correlate hypothermia to other markers of immune dysfunction, such as such as decreased monocyte human lymphocyte antigen (HLA)-DR expression or ex vivo lipopolysaccharide (LPS)-induced tumor necrosis factor-alpha (TNFα) levels. A future prospective study will provide insight into the association between hypothermia and these other measures of sepsis-induced immunosuppression.

Second, we cannot demonstrate causality with this retrospective analysis. Consistent with previous studies (2), the hypothermic patients in our study were sicker than the non-hypothermic patients, with significantly higher APACHE II scores. Thus, it is possible that the increased incidence of persistent lymphopenia in this population was due to increased disease severity. We attempted to control for this by performing a multivariable analysis that included potential confounders, such as age, APACHE II score, comorbidities and source of sepsis, as additional independent variables.

Third, methods of body temperature measurement were not standardized and not recorded in the electronic medical record from which our data was extracted. Given that most of the patients were diagnosed with sepsis in the emergency department where the usual method of temperature measurement is oral or axillary, we presume that most temperature measurements included in this study were peripheral rather than core. Since peripheral temperatures tend to be slightly lower than core, some patients with borderline hypothermia may have been misallocated to the hypothermic group. However, we were conservative in our definition of hypothermia, choosing a cutoff value of 36.0°C rather than 36.5°C which has used in other recent studies (2,12), so we feel our conclusions are sound.

Finally, this study does not address the impact of warming hypothermic septic patients on clinical outcomes or immune function. All the hypothermic patients included in this study were warmed to normothermia according to institutional protocol. Further optimal management of these patients is yet to be elucidated.

Conclusions

Hypothermia within 24 hours of presentation predicts persistent lymphopenia and is associated with increased short- and long-term mortality. Hypothermia may be a useful prognostic factor to identify patients at highest risk for sepsis-induced immunosuppression.

Supplementary Material

Supplemental Digital Content 1. Supplemental Digital Content 1.

Supplemental Table 1. Immunosuppressive medications and immunological diseases leading to patient exclusion. pdf

Supplemental Digital Content 2. Supplemental Digital Content 2.

Supplemental Figure 1. Flowchart of included and excluded patients. pdf

Supplemental Digital Content 3. Supplemental Digital Content 3.

Supplemental Figure 2. Kaplan-Meier survival analysis according to hypothermia group. pdf

Supplemental Digital Content 4. Supplemental Digital Content 4.

Supplemental Table 2. Baseline characteristics of patients stratified by presence of persistent lymphopenia. pdf

Acknowledgments

Sources of Funding: Anne Drewry was supported by the Foundation for Anesthesia Education and Research and the Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 from the National Center for Advancing Translational Sciences. Brian Fuller was supported by the Institute of Clinical and Translation Sciences grant UL1 TR000448 and KL2 TR000450. Richard Hotchkiss was supported by National Institute of Health grants GM 44118 and GM 55194. Richard Hotchkiss reports receiving grant support from MedImmune, Bristol-Myers Squibb, Agennix, and Aurigene.

The authors thank Karen Steger-May, with the Division of Biostatistics at Washington University in St. Louis, for her review of this paper and statistical services. Dr. Drewry was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1 TR000448 and the Foundation for Anesthesia Education and Research. Dr. Fuller was supported by the Washington University Institute of Clinical and Translational Sciences grant UL1 TR00448 and KL2 TR000450. Dr. Hotchkiss was supported by NIH grants GM 44118 and GM 55194.

Footnotes

This study was performed at Washington University School of Medicine and Barnes-Jewish Hospital, St. Louis, MO 63110.

Conflicts of Interest

Anne Drewry, Brian Fuller, and Lee Skrupky have no competing interests to declare.

Copyright form disclosures: Dr. Drewry received grant support from the FAER grant (grant pending) and received support for article research from the National Institutes of Health (NIH). Her institution received grant support from UL1 TR000448. Dr. Fuller received support for article research from the NIH. His institution received grant support from KL2 TR000450. Dr. Skrupky received support for article research from the NIH. His institution received grant support from NIH/National Center for Advancing Translational Sciences (NCATS), CTSA grant UL1TR000448. Dr. Hotchkiss consulted for Glaxo and received support for article research from the NIH. His institution received grant support from the NIH.

References

  • 1.Launey Y, Nesseler N, Malledant, et al. Clinical review: Fever in septic ICU patients – friend or foe? Critical Care. 2011;15:222. doi: 10.1186/cc10097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Kushimoto S, Gando S, Saitoh D, et al. The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: an analysis from a multicenter, prospective survey of severe sepsis. Critical Care. 2013;17:R271. doi: 10.1186/cc13106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Kurtz A, Sessler DI, Lenhardt Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. Study of the Wound Infection and Temperature Group. N Eng J Med. 1996;334:1209–1215. doi: 10.1056/NEJM199605093341901. [DOI] [PubMed] [Google Scholar]
  • 4.Geurts M, Macleod MR, Kollmer R, et al. Therapeutic hypothermia and the risk of infection: a systemic review and meta-analysis. Crit Care Med. 2014;42:231–242. doi: 10.1097/CCM.0b013e3182a276e8. [DOI] [PubMed] [Google Scholar]
  • 5.Jenkins DD, Lee T, Chiuzan, et al. Altered circulating leukocytes and their chemokines in a clinical trial of therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy. Pediatr Crit Care Med. 2013;14:786–795. doi: 10.1097/PCC.0b013e3182975cc9. [DOI] [PubMed] [Google Scholar]
  • 6.Marik PE, Zaloga GP and the Norasept II Study Investigators. Hypothermia and cytokines in septic shock. Intensive Care Med. 2000;26:716–721. doi: 10.1007/s001340051237. [DOI] [PubMed] [Google Scholar]
  • 7.Arons MM, Wheeler AP, Bernard GR, et al. Effects of ibuprofen on the physiology and survival of hypothermic sepsis. Ibuprofen in Sepsis Study Group. Crit Care Med. 1999;27:699–707. doi: 10.1097/00003246-199904000-00020. [DOI] [PubMed] [Google Scholar]
  • 8.Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppresion: from cellular dysfunctions to immunotherapy. Lancet Infect Dis. 2013;13:862–874. doi: 10.1038/nri3552. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Drewry AM, Samra N, Skrupky LP, et al. Persistent lymphopenia after diagnosis of sepsis predicts mortality. Shock. 2014;42:383–391. doi: 10.1097/SHK.0000000000000234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol. 2005;174:3765–3772. doi: 10.4049/jimmunol.174.6.3765. [DOI] [PubMed] [Google Scholar]
  • 11.Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATA/SIS International Sepsis Definitions Conference. Crit Care Med. 2003;31:1250–1256. doi: 10.1097/01.CCM.0000050454.01978.3B. [DOI] [PubMed] [Google Scholar]
  • 12.Young PJ, Saxena M, Beasley R, et al. Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Med. 2012;38:437–444. doi: 10.1007/s00134-012-2478-3. [DOI] [PubMed] [Google Scholar]
  • 13.Meisel C, Shefold JC, Schowski PR, et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med. 2009;180:640–648. doi: 10.1164/rccm.200903-0363OC. [DOI] [PubMed] [Google Scholar]
  • 14.Hall MW, Knatz NL, Vetterly C, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37:525–532. doi: 10.1007/s00134-010-2088-x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Digital Content 1. Supplemental Digital Content 1.

Supplemental Table 1. Immunosuppressive medications and immunological diseases leading to patient exclusion. pdf

Supplemental Digital Content 2. Supplemental Digital Content 2.

Supplemental Figure 1. Flowchart of included and excluded patients. pdf

Supplemental Digital Content 3. Supplemental Digital Content 3.

Supplemental Figure 2. Kaplan-Meier survival analysis according to hypothermia group. pdf

Supplemental Digital Content 4. Supplemental Digital Content 4.

Supplemental Table 2. Baseline characteristics of patients stratified by presence of persistent lymphopenia. pdf

RESOURCES